Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study

Conflict of interest

RK, SY, AN and TM are employees of Teijin Pharma Limited. RN has received honoraria from Astellas Pharma Inc., Astra Zeneca K.K., Boehringer Ingelheim Japan, Inc., Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd., Medtronic Japan Co., Ltd., Novo Nordisk Pharma Inc., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Taisho Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Abbott Japan LLC; research funding from Mitsubishi Electric Corp.; and subsidies or donations from Abbott Japan LLC, Boehringer Ingelheim Japan, Inc., Eli Lilly Japan K.K., Sumitomo Pharma Co., Ltd., Arkley Inc., and Taisho Pharmaceutical Co., Ltd.

Ethical approval

This article does not contain any studies with human subjects performed by any of the authors.

留言 (0)

沒有登入
gif